PDF(Pubmed)
Abstract：
UNASSIGNED: Triple negative breast cancer (TNBC) represents a highly aggressive breast cancer subtype, historically managed with chemotherapy regimens predominantly involving anthracyclines and taxanes, yielding unfavorable prognoses. This review endeavors to offer a thorough examination of the present state of treatment strategies for early stage triple negative breast cancer (eTNBC), with a particular emphasis on immunotherapy modalities, combination therapies, predictive biomarkers, and ongoing clinical trials. The principal aim of this review is to meticulously assess the available literature, ascertain significant discoveries, and engage in discussions regarding their potential implications for future research endeavors, clinical applications, and policy formulation.
UNASSIGNED: This review was conducted using PubMed and Google Scholar databases, with the latest update performed in March 2023. The search strategy was designed to ensure a comprehensive analysis of the literature, with a focus on recent advancements.
UNASSIGNED: We critically assess the current eTNBC treatment landscape, covering efficacy and limitations of monotherapy, combination therapies, and predictive biomarkers. We highlight promising results from recent trials, address controversies surrounding chemotherapy, and explore optimal approaches for adjuvant and neoadjuvant therapy (NAT). Insights into personalized treatment strategies, ongoing trials, and future perspectives are provided, advancing our understanding of therapeutic options for eTNBC.
UNASSIGNED: Through a comprehensive analysis of the literature, this review highlights the potential of immunotherapy, particularly in combination with chemotherapy, as a promising approach for treating eTNBC. However, further research is warranted to optimize treatment strategies, refine patient selection criteria, and identify reliable biomarkers for predicting response to immune checkpoint inhibitors (ICIs). The findings of this review hold significant implications for future research, clinical practice, and policy-making, offering valuable insights into the current challenges and advancements in eTNBC treatment. Ultimately, this knowledge can contribute to improved patient outcomes, enhanced quality of life, and the development of more effective therapeutic approaches for eTNBC.
UNASSIGNED: This review was conducted using PubMed and Google Scholar databases, with the latest update performed in March 2023. The search strategy was designed to ensure a comprehensive analysis of the literature, with a focus on recent advancements.
UNASSIGNED: We critically assess the current eTNBC treatment landscape, covering efficacy and limitations of monotherapy, combination therapies, and predictive biomarkers. We highlight promising results from recent trials, address controversies surrounding chemotherapy, and explore optimal approaches for adjuvant and neoadjuvant therapy (NAT). Insights into personalized treatment strategies, ongoing trials, and future perspectives are provided, advancing our understanding of therapeutic options for eTNBC.
UNASSIGNED: Through a comprehensive analysis of the literature, this review highlights the potential of immunotherapy, particularly in combination with chemotherapy, as a promising approach for treating eTNBC. However, further research is warranted to optimize treatment strategies, refine patient selection criteria, and identify reliable biomarkers for predicting response to immune checkpoint inhibitors (ICIs). The findings of this review hold significant implications for future research, clinical practice, and policy-making, offering valuable insights into the current challenges and advancements in eTNBC treatment. Ultimately, this knowledge can contribute to improved patient outcomes, enhanced quality of life, and the development of more effective therapeutic approaches for eTNBC.
摘要：
■三阴性乳腺癌（TNBC）代表了一种高度侵袭性的乳腺癌亚型，历史上使用主要涉及蒽环类和紫杉烷类的化疗方案进行管理，产生不利的预后。这篇综述致力于全面检查早期三阴性乳腺癌（eTNBC）的治疗策略的现状。特别强调免疫治疗方式，联合疗法,预测性生物标志物，和正在进行的临床试验。这篇综述的主要目的是仔细评估现有文献，确定重大发现，并参与讨论它们对未来研究工作的潜在影响，临床应用，和政策制定。
■这项审查是使用PubMed和GoogleScholar数据库进行的，最新更新于2023年3月进行。搜索策略旨在确保对文献进行全面分析，专注于最近的进步。
■我们严格评估当前的eTNBC治疗前景，涵盖单一疗法的疗效和局限性，联合疗法,和预测性生物标志物。我们强调了最近试验的有希望的结果，解决围绕化疗的争议，并探索辅助和新辅助治疗（NAT）的最佳方法。对个性化治疗策略的见解，正在进行的试验,并提供了未来的前景，推进我们对eTNBC治疗方案的理解。
■通过对文献的综合分析，这篇综述强调了免疫治疗的潜力，特别是联合化疗，作为治疗eTNBC的一种有希望的方法。然而,需要进一步的研究来优化治疗策略，完善患者选择标准，并确定可靠的生物标志物，以预测对免疫检查点抑制剂（ICI）的反应。这篇综述的发现对未来的研究具有重要意义，临床实践，和政策制定，提供对eTNBC治疗当前挑战和进步的宝贵见解。最终,这些知识有助于改善患者的预后，提高生活质量，以及开发更有效的eTNBC治疗方法。
■这项审查是使用PubMed和GoogleScholar数据库进行的，最新更新于2023年3月进行。搜索策略旨在确保对文献进行全面分析，专注于最近的进步。
■我们严格评估当前的eTNBC治疗前景，涵盖单一疗法的疗效和局限性，联合疗法,和预测性生物标志物。我们强调了最近试验的有希望的结果，解决围绕化疗的争议，并探索辅助和新辅助治疗（NAT）的最佳方法。对个性化治疗策略的见解，正在进行的试验,并提供了未来的前景，推进我们对eTNBC治疗方案的理解。
■通过对文献的综合分析，这篇综述强调了免疫治疗的潜力，特别是联合化疗，作为治疗eTNBC的一种有希望的方法。然而,需要进一步的研究来优化治疗策略，完善患者选择标准，并确定可靠的生物标志物，以预测对免疫检查点抑制剂（ICI）的反应。这篇综述的发现对未来的研究具有重要意义，临床实践，和政策制定，提供对eTNBC治疗当前挑战和进步的宝贵见解。最终,这些知识有助于改善患者的预后，提高生活质量，以及开发更有效的eTNBC治疗方法。
